Peptide Monographs

Mazdutide and Tirzepatide side by side

Mazdutide and Tirzepatide are both indexed under Incretin receptor agonists. Every cell below carries the record it came from, and an axis with no retrieved value reads Unknown rather than being filled by inference.

Summary

Both are once-weekly dual agonists built on a GLP-1 receptor backbone, and both have phase 3 literature, but their second receptor differs: the cited 2022 EClinicalMedicine paper describes mazdutide as a GLP-1 and glucagon receptor dual agonist, while the cited 2021 paper describes tirzepatide as a dual GIP and GLP-1 receptor agonist.

[1, 2, 3, 4, 5]

Side by side

Curated comparison axes for Mazdutide and Tirzepatide
AxisMazdutideTirzepatide
Reported mechanismA GLP-1 receptor and glucagon receptor dual agonist, per the retrieved records.[1, 9]Dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 receptor.[4]
Molecular formulaC207H317N45O65[6]C225H348N48O68[14]
Molecular weight4476 g/mol[6]4813 g/mol[14]
FDA application registerA query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[7]A query of the FDA Drugs@FDA application register on 2026-10-09 returned 2 application record(s) for this compound name (including NDA215866, NDA217806, marketed as MOUNJARO, MOUNJARO KWIKPEN, MOUNJARO (AUTOINJECTOR), ZEPBOUND, ZEPBOUND KWIKPEN, ZEPBOUND (AUTOINJECTOR)). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.[15]

Where the two literatures diverge

Receptor profile and trial populations diverge. The cited mazdutide records are Chinese trials, including the 2025 New England Journal of Medicine paper in Chinese adults with obesity or overweight and the 2026 Nature comparison with dulaglutide in type 2 diabetes. The cited tirzepatide records are the SURMOUNT and SURPASS programmes, including the 2022 New England Journal of Medicine obesity trial. Tirzepatide returned an FDA application record under its generic name, recorded on its page; mazdutide did not.

[1, 2, 3, 4, 5]

Where this page sits

Full pages: Mazdutide and Tirzepatide.

Shared class: Incretin receptor agonists.

Other pairs in the same class

All side-by-side pages: index.

Sources

  1. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine (2022). pmid:36247927
  2. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. The New England journal of medicine (2025). pmid:40421736
  3. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature (2026). pmid:41407860
  4. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet (2021). pmid:34186022
  5. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med (2022). pmid:35658024
  6. PubChem Compound Summary for CID 167312357, Mazdutide. PubChem, National Library of Medicine (2026). pubchem:167312357
  7. Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:mazdutide
  8. IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study. EClinicalMedicine (2021). pmid:34430840
  9. A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nature communications (2022). pmid:35750681
  10. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nature communications (2023). pmid:38092790
  11. Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Diabetes care (2024). pmid:37943529
  12. Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature (2026). pmid:41407859
  13. Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Frontiers in endocrinology (2024). pmid:38440786
  14. PubChem Compound Summary for CID 166567236, tirzepatide. PubChem, National Library of Medicine (2026). pubchem:166567236
  15. Drugs@FDA application register query for this compound, 2 application(s) returned: NDA215866, NDA217806. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:tirzepatide
  16. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med (2021). pmid:34170647
  17. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med (2024). pmid:38856224
  18. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med (2025). pmid:39555826

On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.

Related resources